The DOI matches its Crossref record; 106 of the 109 references it cites were found in a registry or an index.
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
Open accessPublished version of a preprint
Abstract
and RBD epitopes on SARS-CoV-2 spike. Moreover, a 3.4 Å cryo-electron microscopy (cryo-EM) structure of a neutralizing monoclonal Fab-spike complex revealed an epitope that blocks ACE2 receptor binding. Modeling based on these structures suggested different potentials for inter-spike crosslinking by IgGs on viruses, and characterized IgGs would not be affected by identified SARS-CoV-2 spike mutations. Overall, our studies structurally define a recurrent anti-SARS-CoV-2 antibody class derived from VH3-53/VH3-66 and similarity to a SARS-CoV VH3-30 antibody, providing criteria for evaluating vaccine-elicited antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the plasma neutralizing activity, and the relative numbers of RBD-specific memory B cells were equivalent to individuals who recovered from natural infection7,8.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“As expected, plasma neutralizing activity was directly correlated to anti-S and -RBD binding titers in ELISAs7,8 (Fig. 1c, d, and Extended Data Fig. 2a–d).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“In addition, antibodies that share the same combination of IGHV and IGLV genes in vaccinees comprised 39% of all the clonal sequences (Extended Data Fig. 4b) and 59% when combined with naturally infected individuals7,8 (Fig. 2f), and some of these antibodies were nearly identical (Extended Data Table 3 and 4).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“Class 1 and 2 antibodies are among the most potent and also the most abundant antibodies7,8,21,22,25,39.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“Consistent with the plasma neutralization results, the geometric mean neutralization half-maximal inhibitory concentration of the Pfizer-BioNTech and Moderna vaccinee antibodies were not significantly different from each other or to antibody collections obtained from naturally infected individuals 1.3 or 6.2 months after infection (Fig. 3a and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“In anti-RBD ELISAs the mean half-maximal effective concentration (EC50) was higher than that observed in infected individuals after 6.2 months but not significantly different from antibodies obtained 1.3 months after infection (Extended Data Fig. 6a, and Table 5 and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“Numerous neutralizing anti-RBD monoclonal antibodies (mAbs) have been characterized, the most potent of which block the RBD-ACE2 interaction (16, 17, 22–24, 32–37).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [32]
In the citing paper
“Antibodies binding to the RBD can potently block attachment of the virus to ACE2 and thereby neutralize the virus”
From SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 (2021) · cites this paper as Barnes et al., 2020
In the citing paper
“Their engagement with the RBD is dictated by CDR-H1 and CDR-H2, while the CDR-H3 is characteristically short and makes rather few interactions”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Barnes et al., 2020
In the citing paper
“A number of public antibody responses have been reported for SARS-CoV-2, principal among these being VH3–53/VH3–66 and VH1–58 (VH3–30 is also found, but the antibodies are not potent neutralizers) (Yuan et al., 2020; Barnes et al., 2020; Dejnirattisai et al., 2021).”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Barnes et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Self-citationGuindon, S., Dufayard, J.-F., Lefort, V., Anisimova, M., Hordijk, W., & Gascuel, O. (2010) · Systematic Biology · doi:10.1093/sysbio/syq010 · Cited by 18,376
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega
Sievers, F., Wilm, A., Dineen, D., Gibson, T., Karplus, K., Li, W.-Z., Lopez, R., McWilliam, H., Remmert, M., Söding, J., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.75 · Cited by 15,576
Flagged first, then by citations
3 of the 109 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 803
COVID-19 pandemic and the answer of science: a year in review
OLIVEIRA, E. A., Oliveira, M. C. L., Martelli, D. R. B., Colosimo, E. A., Silva, L. R., Lanza, K., Júnior, H. M., & Silva, A. C. S. E. (2021) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202120210543 · Cited by 12
Pandemic strategies with computational and structural biology against COVID-19: A retrospective
Liu, C., Lu, C.-H., & Lin, L. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.11.040 · Cited by 9
Cia, G., Pucci, F., & Rooman, M. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042078 · Cited by 9
Roeder, A. J., Koehler, M. A., Jasbi, P., McKechnie, D., Vanderhoof, J., Edwards, B. A., González‐Moa, M. J., Seit‐Nebi, A. S., Svarovsky, S. A., & Lake, D. F. (2022) · Vaccines · doi:10.3390/vaccines10091459 · Cited by 9
Antibody Display of cell surface receptor Tetraspanin12 and SARS-CoV-2 spike proteinPreprint
Hsieh, F.-L., & Chang, T.-H. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.29.446300 · Cited by 9
SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus ImmunogenicityPreprint
Joyce, M. G., Chen, W., Sankhala, R. S., Hajduczki, A., Thomas, P. V., Choe, M., Martinez, E. J., Chang, W. C., Peterson, C. E., Morrison, E. B., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3854502 · Cited by 9
Ku, Z., Xie, X., Lin, J., Gao, P., Sahili, A. E., Su, H., Liu, Y., Ye, X., Li, X., Fan, X., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.01.478504 · Cited by 9
Soto, J., Linsley, C. S., Song, Y., Chen, B., Fang, J., Neyyan, J., Davila, R., Lee, B. S., Wu, B. M., & Li, S. (2023) · Nanomaterials · doi:10.3390/nano13172455 · Cited by 9
Cryo EM structures map a post vaccination polyclonal antibody response to canine parvovirus
Hartmann, S. R., Charnesky, A. J., Früh, S. P., López-Astacio, R. A., Weichert, W. S., DiNunno, N. M., Cho, S. H., Bator, C. M., Parrish, C. R., & Hafenstein, S. L. (2023) · Communications Biology · doi:10.1038/s42003-023-05319-7 · Cited by 9
Li, X., Zhang, Y., He, L., Si, J., Qiu, S., He, Y., Wei, J., Wang, Z., Xie, L., Li, Y., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.66369 · Cited by 8
Bhiman, J. N., & Moore, P. L. (2022) · Immunological Reviews · doi:10.1111/imr.13086 · Cited by 7
Zhao, Y., Zhao, Y., Xie, L.-K., Li, Q., Zhang, Y., Zang, Y., Li, X., Zhang, L., & Yang, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076281 · Cited by 8
Rienzo, L. D., Miotto, M., Desantis, F., Grassmann, G., Ruocco, G., & Milanetti, E. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26497 · Cited by 8
Poumbourios, P., Langer, C., Boo, I., Zakir, T., Akerman, A., Milogiannakis, V., Aggarwal, A., Johnstone, B. A., Ha, J., Coulibaly, F., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1010981 · Cited by 8
Antibody drugs targeting SARS-CoV-2: Time for a rethink?
Liang, L., Wang, B., Zhang, Q., Zhang, S., & Zhang, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116900 · Cited by 8
The Analyses of High Infectivity Mechanism of SARS-CoV-2 and Its Variants
Lu, Y., Zhao, T., Lu, M. C., Zhang, Y., Yao, X., Wu, G., Dai, F., Zhang, F., & Zhang, G. (2021) · COVID · doi:10.3390/covid1040054 · Cited by 8
COVID-19 Vaccine: Review of the Mechanism of Action of Different Types of Vaccine
Wong, L.-A., Yap, C. G., Jahan, N. K., & Pillai, N. (2022) · OALib · doi:10.4236/oalib.1108624 · Cited by 8
Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants
Li, L., Gao, M., Jiao, P., Zu, S., Deng, Y., Wan, D., Cao, Y., Duan, J., Aliyari, S. R., Li, J., et al. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00794-7 · Cited by 8
Mashimo, Y., Yamazaki, K., Kageyama, T., Tanaka, S., Taniguchi, T., Matsushita, K., Igari, H., Hanaoka, H., Yokote, K., Nakajima, H., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.10.015 · Cited by 10
Bains, A., Guan, W., & LiWang, P. J. (2023) · Viruses · doi:10.3390/v15091901 · Cited by 9
SARS-COV-2 Omicron variants conformationally escape a rare quaternary antibody binding mode
Goike, J., Hsieh, C., Horton, A. P., Gardner, E. C., Zhou, L., Bartzoka, F., Wang, N., Javanmardi, K., Herbert, A. S., Abbasi, S. A., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05649-6 · Cited by 8
Lee, C. Y., Amrun, S. N., Chee, R. S., Goh, Y. S., Mak, T. M., Octavia, S., Yeo, N. K., Chang, Z. W., Tay, M. Z., Torres‐Ruesta, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.08.332544 · Cited by 8
Baisa, G. A., Rancour, D. M., Mansfield, K. G., Burns, M. A., Martin, L., Cunha, D., Fischer, J., Muecksch, F., Hatziioannou, T., Bieniasz, P. D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.21203/rs.3.rs-137857/v1 · Cited by 8
Self-citationIsolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ SubjectsPreprint
Jennewein, M. F., MacCamy, A. J., Akins, N. R., Feng, J., Homad, L. J., Hurlburt, N. K., Seydoux, E., Wan, Y.-H., Stuart, A. B., Edara, V. V., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.23.436684 · Cited by 9
Abela, I. A., Pasin, C., Schwarzmüller, M., Epp, S., Sickmann, M. E., Schanz, M. M., Rusert, P., Weber, J., Schmutz, S., Audigé, A., et al. (2021) · medRxiv · doi:10.1101/2021.04.21.21255410 · Cited by 8
SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique Spike binding propertiesPreprint
Fenwick, C. W., Turelli, P., Ni, D., Perez, L. H., Lau, K., Lana, E., Pellaton, C., Raclot, C., Esteves-Leuenberger, L., Campos, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.18.484873 · Cited by 8
Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal modelsPreprint
Cohen, A. A., van Doremalen, N., Greaney, A. J., Andersen, H., Sharma, A., Starr, T. N., Keeffe, J., Fan, C.-H., Schulz, J. E., Gnanapragasam, P. N. P., et al. (2022) · bioRxiv · doi:10.1101/2022.03.25.485875 · Cited by 5
Self-citationHederman, A. P., Natarajan, H., Wiener, J. A., Wright, P. F., Bloch, E. M., Tobian, A. A. R., Redd, A. D., Blankson, J. N., Rottenstreich, A., Zarbiv, G., et al. (2022) · medRxiv · doi:10.1101/2022.09.15.22280000 · Cited by 8
Absolute concentration estimation of COVID-19 convalescent and post-vaccination IgG antibodies
Klegerman, M. E., Peng, T., Seferovich, I., Rahbar, M. H., Hessabi, M., Tahanan, A., Wanger, A. R., Grimes, C. Z., Ostrosky‐Zeichner, L., Koster, K. J., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311777 · Cited by 8
Mapping the antibody response to Lassa virus vaccination of non-human primates
Enriquez, A. S., Díaz-Avalos, R., Parekh, D. V., Cooper, C. L., Morrow, G., Geisbert, T. W., Parks, C. L., Hastie, K. M., & Saphire, E. O. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105673 · Cited by 7
Design of a Multi-Valent SARS-CoV-2 Peptide Vaccine for Broad Immune Protection via Deep Learning
Feng, Z., Pang, X., Xu, Q., Gu, Z., Li, S., Zhu, L., & Li, H. (2025) · Engineering · doi:10.1016/j.eng.2025.04.025 · Cited by 7
Lee, I., Lan, Y.-H., Wu, P., Wu, Y., Chen, Y.-H., Tseng, S.-C., Kuo, T.-J., Sun, C., Jan, J., Ma, H., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2149353 · Cited by 8
Increasing sensitivity of antibody-antigen interactions using photo-cross-linking
de la Pena, A. T. T., Sewall, L. M., Rocha, R. D. P. F., Jackson, A., Pratap, P., Bangaru, S., Cottrell, C., Mohanty, S., Shaw, A., & Ward, A. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100509 · Cited by 8
The D Gene in CDR H3 Determines a Public Class of Human Antibodies to SARS-CoV-2
Yuan, M., & Wilson, I. A. (2024) · Vaccines · doi:10.3390/vaccines12050467 · Cited by 7
Castro, A., Öztürk, K., Zanetti, M., & Carter, H. K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246731 · Cited by 8
Deamidation drives molecular aging of the SARS-CoV-2 spike protein receptor-binding motif
Lorenzo, R., Defelipe, L. A., Aliperti, L., Niebling, S., Custódio, T. F., Löw, C., Schwarz, J., Remans, K., Craig, P. O., Otero, L. H., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101175 · Cited by 7
Sariol, C. A., Serrano-Collazo, C., Ortiz, E. J., Pantoja, P., Cruz, L. A., Arana, T., Atehortua, D., Pabon-Carrero, C., & Espino, A. M. (2021) · Viruses · doi:10.3390/v13122405 · Cited by 6
Three-dimensional insights into human enveloped viruses in vitro and in situ
Vankadari, N., Shepherd, D. C., Carter, S. D., & Ghosal, D. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210433 · Cited by 7
Ueno, M., Iwata‐Yoshikawa, N., Matsunaga, A., Okamura, T., Saito, S., Ashida, S., Yoshida, I., Nagashima, M., Asakura, H., Yaoita, Y., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105297 · Cited by 7
Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain
Gao, X., Fan, L., Zheng, B., Li, H., Wang, J., Zhang, L., Li, J., & Zhu, F. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2055373 · Cited by 8
AIRRscape: An interactive tool for exploring B-cell receptor repertoires and antibody responses
Waltari, E., Nafees, S., Wong, J., McCutcheon, K. M., & Pak, J. E. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010052 · Cited by 7
Li, Y., Kong, Y., Yu, X., Yu, W., Wen, K., Shen, J., & Wang, Z. (2023) · One Health Advances · doi:10.1186/s44280-023-00013-z · Cited by 7
Wendel, S., Fachini, R. M., Fontão‐Wendel, R., Mello, R., Velasquez, C. V., Machado, R. R. G., Brito, M., Amaral, M., Soares, C. P., Achkar, R., et al. (2021) · Transfusion · doi:10.1111/trf.16714 · Cited by 6
Thermodynamics and kinetics in antibody resistance of the 501Y.V2 SARS-CoV-2 variant
Ngô, S. T., Nguyen, T. H., Pham, D.-H., Tùng, N. T., & Nam, P. C. (2021) · RSC Advances · doi:10.1039/d1ra04134g · Cited by 7
Noval, M. G., Kaczmarek, M. E., Koide, A., Rodriguez-Rodriguez, B. A., Louie, P., Tada, T., Hattori, T., Panchenko, T., Romero, L. A., Teng, K. W., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.15.252353 · Cited by 7
The N-glycosylation sites and Glycan-binding ability of S-protein in SARS-CoV-2 CoronavirusPreprint
Chen, W., Hui, Z., Ren, X., Luo, Y., Shu, J. H., Yu, H., & Li, Z. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.01.406025 · Cited by 7
Fenwick, C. W., Turelli, P., Pellaton, C., Farina, A., Campos, J., Raclot, C., Pojer, F., Cagno, V., Pantaleo, G., & Trono, D. (2021) · medRxiv · doi:10.1101/2021.04.08.21255150 · Cited by 7
Yu, J., Yao, W., Hu, Y., Wu, S., Li, J., Zhou, H., Hong, K., Chen, J., Liu, L., Lan, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.03.467182 · Cited by 7
Sokal, A., Broketa, M., Meola, A., Spaeth, G. B., Fernández, I., Fourati, S., Azzaoui, I., Selle, A. D. L., Vandenberghe, A., Roeser, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.21.473528 · Cited by 7
Cofas‐Vargas, L. F., Mendoza-Espinosa, P., Montalvo-Sandoval, F. D., Rodriguez, S. P., Rauda-Ceja, J. A., Hernández‐Peralta, P., Durán-Vargas, A., Trujillo‐Roldán, M. A., Valdez‐Cruz, N. A., & García‐Hernández, E. (2025) · mAbs · doi:10.1080/19420862.2025.2575083 · Cited by 8
Antibody-mediated diversification of primary and secondary humoral immune responses
Schaefer-Babajew, D. J., Binet, L., Santos, G. S. S., Ruprecht, C., Deimel, L. P., ElTanbouly, M. A., Gharrassi, D., dos Reis, G. L., Uhe, C., Yao, K.-H., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20252590 · Cited by 6
Self-citationChuang, G., Shen, C., Cheung, C. S., Gorman, J., Creanga, A., Joyce, M. G., Leung, K., Rawi, R., Wang, L., Yang, E. S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.662909 · Cited by 6
Teruel, N., Crown, M. R., Rajsbaum, R., Bashton, M., & Najmanovich, R. (2025) · Virus Evolution · doi:10.1093/ve/veaf027 · Cited by 7
Innovative vaccine approaches—a Keystone Symposia report
Cable, J., Rappuoli, R., Klemm, E. J., Kang, G., Mutreja, A., Wright, G. J., Pizza, M., Castro, S. A., Hoffmann, J. P., Alter, G., et al. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14739 · Cited by 6
Almanza, G., Clark, A. E., Kouznetsova, V. L., Olmedillas, E., Castro, A., Tsigelny, I. F., Wu, Y., Gao, G. F., Leibel, S. L., Bray, W. A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010686 · Cited by 5
Rong, Y., Wang, X., Mao, W., Yuan, F., Chen, M., Wang, S., Wang, P. G., Wu, Z., He, Y., & Kong, Y. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00383 · Cited by 6
Mutational Analysis of Circulating Omicron SARS-CoV-2 Lineages in the Al-Baha Region of Saudi Arabia
Almalki, S. S. R., Izhari, M. A., Alyahyawi, H. E., Alatawi, S. K., Klufah, F., Ahmed, W. A. M., & Alharbi, R. (2023) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s419859 · Cited by 6
Khan, M. S. A. A., Jakob, V., Singh, R., Rajmani, R. S., Kumar, S., Lemoine, C., Kleanthous, H., Ringe, R. P., Dubois, P. M., & Varadarajan, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122759 · Cited by 6
Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak
Maciorowski, D., Ogaugwu, C., Durvasula, S. R., Durvasula, R. V., & Kunamneni, A. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220979579 · Cited by 6
Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
Hong, J., Jhun, H., Choi, Y.-O., Taitt, A. S., Bae, S., Lee, Y.-M., Song, C., Yeom, S. C., & Kim, S. (2021) · Immune Network · doi:10.4110/in.2021.21.e8 · Cited by 6
Web resources facilitate drug discovery in treatment of COVID-19
Mei, L., Jin, Y., Wang, Z., Hao, G., & Yang, G. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.04.018 · Cited by 7
Synthetic proteins for COVID-19 diagnostics
Schein, C. H., Levine, C. B., McLellan, S., Negi, S. S., Braun, W. A., Dreskin, S. C., Anaya, E. S., & Schmidt, J. G. (2021) · Peptides · doi:10.1016/j.peptides.2021.170583 · Cited by 6
Rey, F. A. (2021) · Comptes Rendus Biologies · doi:10.5802/crbiol.53 · Cited by 11
Ovchinnikov, V., & Karplus, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816634 · Cited by 6
Delta variant: Partially sensitive to vaccination, but still worth global attention
Zhang, M., He, Y.-C., & Jie, Z. (2022) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2022-0026 · Cited by 6
Lunderberg, J. M., Dutta, S., Collier, A.-R. Y., Lee, J.-S., Hsu, Y., Wang, Q., Zheng, W., Hao, S., Zhang, H., Feng, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032574 · Cited by 7
Rationalizing Random Walks: Replicating Protective Antibody Trajectories
Remmel, J. L., & Ackerman, M. E. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.01.001 · Cited by 6
An in Silico Scientific Basis for LL-37 as a Therapeutic and Vitamin D as Preventive for Covid-19.Preprint
Lokhande, K. B., Banerjee, T., Swamy, K. V., & Deshpande, M. S. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12928202.v1 · Cited by 6
Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395
Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines
Bangaru, S., Jackson, A. M., Copps, J., Fernández‐Quintero, M. L., Torres, J. L., Richey, S. T., Nogal, B., Sewall, L. M., de la Peña, A. T., Rehman, A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115986 · Cited by 6
Cohen, A. A., Keeffe, J. R., Rorick, A. V., Rho, S., Fils, A.-C. I. P., Manasyan, L., Gao, H., Gnanapragasam, P. N. P., Funke, H. H., Randolph, T. W., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113649 · Cited by 5
A novel plasma proteomic‐based model for predicting liver fibrosis in HIV/HBV co‐infected adults
Yuan, R., Zhang, Y.-X., Deng, L.-P., Yu, X.-X., Zhuang, K., Chen, X.-P., Cao, Q., Ping, H., Ke, H.-N., Gui, X., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28222 · Cited by 6
Function and mechanism of bispecific antibodies targeting SARS-CoV-2
Li, Z., Zhang, Z., Rosen, S. T., & Feng, M. (2024) · Cell Insight · doi:10.1016/j.cellin.2024.100150 · Cited by 5
Suryadevara, N., Kose, N., Bangaru, S., Binshtein, E., Munt, J. E., Martinez, D. R., Schäfer, A., Myers, L., Scobey, T., Carnahan, R. H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178880 · Cited by 6
Adeleke, R. A., Sahler, J., Choi, A., Roth, K., Upadhye, V., Ezzatpour, S., Imbiakha, B., Khomandiak, S., Diaz, A. N., Whittaker, G. R., et al. (2025) · Science Advances · doi:10.1126/sciadv.adq4545 · Cited by 5
Li, S., Ye, F., Zheng, Y., Wang, J., Peng, H., Zhu, L., Chen, L., Yu, T., Ge, H., He, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202417534 · Cited by 4
501Y.V2 spike protein resists the neutralizing antibody in atomistic simulations
Ngô, S. T. (2022) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2022.107636 · Cited by 5
Verkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031646 · Cited by 5
Anzai, I., Fujita, J., Ono, C., Kosaka, Y., Miyamoto, Y., Shichinohe, S., Takada, K., Torii, S., Taguwa, S., Suzuki, K., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03655-23 · Cited by 5
Ma, M. T., Jiang, Q., Chen, C., Badeti, S., Wang, X., Zeng, C., Evans, D., Bodnar, B. H., Marras, S. A. E., Tyagi, S., et al. (2024) · Journal of Virology · doi:10.1128/jvi.00038-24 · Cited by 5
Dhawan, M. K., Thakur, N., Sharma, M. K., & Rabaan, A. A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117936 · Cited by 5
COVID-19: A Concern for Cardiovascular Disease Patients
Sharma, S. (2020) · Cardiovascular Toxicology · doi:10.1007/s12012-020-09596-0 · Cited by 5
The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal
Tosta, E. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00014 · Cited by 5
Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines
Wang, S., Wu, D., Xiong, H., Wang, J., Tang, Z., Chen, Z., Wang, Y., Zhang, Y., Dong, Y., Lin, X. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952650 · Cited by 7
The nuts and bolts of recombination in the generation of SARS-CoV-2 variants; from XA to XBB
Karim, B., Barary, M., Fereydouni, Z., Sanjari, E., Hosseinzadeh, R., Salehi-Vaziri, ., & Maleki, A. (2024) · Letters in Applied Microbiology · doi:10.1093/lambio/ovae074 · Cited by 5
Quantity of IgG response to SARS-CoV-2 spike glycoprotein predicts pulmonary recovery from COVID-19
Nairz, M., Sahanic, S., Pizzini, A., Boehm, A., Tymoszuk, P., Mitterstiller, A., von Raffay, L., Grubwieser, P., Bellmann‐Weiler, R., Koppelstätter, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07489-6 · Cited by 5
A Highly Potent Antibody Effective Against SARS-CoV-2 Variants of ConcernPreprint
Fenwick, C. W., Turelli, P., Perez, L. H., Pellaton, C., Esteves-Leuenberger, L., Farina, A., Campos, J., Lana, E., Fiscalini, F., Raclot, C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3844718 · Cited by 5
Sokal, A., Spaeth, G. B., Fernández, I., Broketa, M., Azzaoui, I., Selle, A. D. L., Vandenberghe, A., Fourati, S., Roeser, A., Meola, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.17.448459 · Cited by 5
Systemic and mucosal immune signatures of protection against SARS-CoV-2 transmission in humans
Rojo-Fernandez, A., Aslam, S., Alam, F., Escalera, A., Villamandos, V., Caton, B., Megías, G., Gonzalez, A., Buzón, L., Ayllón, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102505 · Cited by 5
Zhou, P., Hartweger, H., MacLean, A. J., Ramos, V., Yao, K.-H., Hernandez, B., wang, Z., Gazumyan, A., & Nussenzweig, M. C. (2026) · Immunity · doi:10.1016/j.immuni.2026.01.027 · Cited by 4
Self-citationIntrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections
Quirk, G., Schoenle, M. V., Peyton, K. L., Uhrlaub, J. L., Lau, B., Liang, C.-Y., Burgess, J. L., Ellingson, K., Beitel, S. C., Romine, J. K., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02162-2 · Cited by 5
AbouYoussef, M. L., Aboelnga, M. M., Hanafy, N. A. N., & El‐Kelany, K. E. (2025) · Scientific Reports · doi:10.1038/s41598-025-06676-5 · Cited by 4
Structural Insights into the SARS-CoV-2 Spike Protein and Its Implications for Antibody Resistance
Yamamoto, Y., & Noguchi, K. (2025) · Biomolecules · doi:10.3390/biom15111489 · Cited by 5
Remesh, S. G., Merz, G. E., Brilot, A. F., Chio, U. S., Rizo, A. N., Pospiech, T. H., Lui, I., Laurie, M. T., Glasgow, J. E., Le, C. Q., et al. (2023) · Structure · doi:10.1016/j.str.2023.01.009 · Cited by 4
Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV-2 Infection
Stagnoli, S., Macari, G., Corsi, P., Capone, B., Vidaurrazaga, A., Ereño‐Orbea, J., Ardá, A., Polticelli, F., Jiménez‐Barbero, J., Abrescia, N. G. A., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c02921 · Cited by 4
Zhang, T., Yang, D., Tang, L., & Hu, Y. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13272 · Cited by 5
Yasa, S., Guirales-Medrano, S., Machado, D. J., Ford, C. T., & Janies, D. A. (2024) · Frontiers in Virology · doi:10.3389/fviro.2024.1419276 · Cited by 4
Dynamics of cytokine and antibody responses in community versus hospital SARS-CoV-2 infections
Singh, T., Macintyre, A. N., Burke, T. W., Anderson, J. G., Petzold, E., Stover, E. L., French, M. J., Oguin, T. H., DeMarco, T., McClain, M. T., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1468871 · Cited by 5
Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine
Myburgh, L., Karsjens, H., Blanas, A., de Ligt, A., van Loon, K., Huijbers, E. J. M., B, J. R. V. B., Engbersen, D. J. M., Rekiki, A., Mignon, C., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126989 · Cited by 4
Liu, Y., Li, C., Wu, Z., Zhao, Y., Yin, T., Liu, X., Hui, J., Wang, Q., Pan, Y., Shan, Y., et al. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1560330 · Cited by 4
Metadata
- Authors
- Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Finkin, S., Hägglöf, T., Hurley, A., Millard, K. G., Weisblum, Y., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., Caskey, M., Robbiani, D. F., Nussenzweig, M. C., & Bjorkman, P. J.
- Affiliations
- California Institute of Technology (US)
- Rockefeller University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Nussenzweig, Michel C.
- ORCID
- Barnes, Christopher O.
- West, Anthony P.
- Hoffmann, Magnus A.G.
- Sharaf, Naima G.
- Hoffman, Pauline R.
- Koranda, Nicholas
- Gristick, Harry B.
- Gaebler, Christian
- Muecksch, Frauke
- Lorenzi, Julio C. Cetrulo
- Finkin, Shlomo
- Hägglöf, Thomas
- Hurley, Arlene
- Millard, Katrina G.
- Weisblum, Yiska
- Schmidt, Fabian
- Bieniasz, Paul D.
- Caskey, Marina
- Robbiani, Davide F.
- Nussenzweig, Michel C.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 182
- Issue
- 4
- Pages
- 828-842.e16
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC7311918
- OpenAlex
- W3036607916
- Cited by
- 795
- References
- 109
- Citations by year
- 2026: 34 · 2025: 49 · 2024: 50 · 2023: 84 · 2022: 151 · 2021: 319 · 2020: 107
- FWCI
- 21.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cell (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by-nc-nd)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, cc-by)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Funders
- National Center for Advancing Translational Sciences (UL1 TR001866)
- Burroughs Wellcome Fund
- Howard Hughes Medical Institute
- Basic Energy Sciences (DE-AC02-76SF00515)
- National Institute of General Medical Sciences (P41GM103393, 2U19AI111825, P50 8 P50 AI150464-13, P01-AI138938-S1)
- Bill and Melinda Gates Foundation (INV-002143)
- Office of Science
- Biological and Environmental Research
- U.S. Department of Energy
- Beckman Institute, California Institute of Technology
- George Mason University
- California Institute of Technology
- National Institutes of Health
- Rockefeller University
- Icahn School of Medicine at Mount Sinai
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- SARS-CoV-2 spike protein, human antibodies, neutralizing antibodies, ACE2 binding, IgG, spike protein mutations, vaccine-elicited antibodies, antibody structure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
